NASDAQ:VRAY - Viewray Stock Price, Forecast & News

Viewray trades on the NASDAQ under the ticker symbol "VRAY."

Viewray Inc (NASDAQ:VRAY) issued its earnings results on Tuesday, November, 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.27) by $0.06. The firm had revenue of $20.90 million for the quarter, compared to analysts' expectations of $20.66 million. Viewray had a negative return on equity of 75.41% and a negative net margin of 110.61%. The business's revenue was up 18.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.39) earnings per share. View Viewray's Earnings History.

Viewray is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Viewray.

Viewray updated its FY 2019 After-Hours earnings guidance on Monday, November, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $$80-95 million, compared to the consensus revenue estimate of $$89.28 million.

9 analysts have issued 12 month target prices for Viewray's shares. Their forecasts range from $5.00 to $9.00. On average, they expect Viewray's stock price to reach $6.44 in the next year. This suggests a possible upside of 60.3% from the stock's current price. View Analyst Price Targets for Viewray.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viewray in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Viewray.

News stories about VRAY stock have trended somewhat negative on Thursday, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Viewray earned a media sentiment score of -1.6 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Viewray.

Some companies that are related to Viewray include Natus Medical (NTUS), AxoGen (AXGN), Cutera (CUTR), TransMedics Group (TMDX), Zynex (ZYXI), BioLife Solutions (BLFS), Stereotaxis (STXS), Semler Scientific (SMLR), Edap Tms (EDAP), BioSig Technologies (BSGM), Rockwell Medical (RMTI), Fonar (FONR), Second Sight Medical Products (EYES), Soleno Therapeutics (SLNO) and electroCore (ECOR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Viewray investors own include Alibaba Group (BABA), Cara Therapeutics (CARA), Corbus Pharmaceuticals (CRBP), Sarepta Therapeutics (SRPT), Square (SQ), Advanced Micro Devices (AMD), Amarin (AMRN), Amicus Therapeutics (FOLD), Iovance Biotherapeutics (IOVA) and Pieris Pharmaceuticals (PIRS).

(VRAY) raised $52 million in an IPO on the week of April 6th 2015. The company issued 4,000,000 shares at $12.00-$14.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and BTIG and Brean Capital were co-managers.

Viewray's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (1.56%), State Street Corp (1.37%), Rhenman & Partners Asset Management AB (0.65%), Kahn Brothers Group Inc. DE (0.35%), Essex Investment Management Co. LLC (0.15%) and Russell Investments Group Ltd. (0.13%). Company insiders that own Viewray stock include Fmr Llc, International Ltd Fosun, James F Dempsey, Orbimed Advisors Llc, Scott William Drake and Shahriar Matin. View Institutional Ownership Trends for Viewray.

VRAY stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Rhenman & Partners Asset Management AB, Essex Investment Management Co. LLC, Perkins Capital Management Inc., Pennsylvania Trust Co, Stephens Inc. AR and Squarepoint Ops LLC. View Insider Buying and Selling for Viewray.

VRAY stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Kahn Brothers Group Inc. DE, Investor AB, Parallel Advisors LLC, Virtu Financial LLC, Raymond James Trust N.A., Allworth Financial LP and Russell Investments Group Ltd.. Company insiders that have bought Viewray stock in the last two years include International Ltd Fosun, Scott William Drake and Shahriar Matin. View Insider Buying and Selling for Viewray.

Shares of VRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of VRAY stock can currently be purchased for approximately $4.02.

Viewray has a market capitalization of $399.61 million and generates $80.96 million in revenue each year. The company earns $-76,400,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. View Additional Information About Viewray.

The official website for Viewray is http://www.viewray.com/.

Viewray's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The company can be reached via phone at 440-703-3210 or via email at [email protected]